NCT00215436

Brief Summary

The purpose of this study is to determine the safety and efficacy of the investigational drug in comparison with a placebo.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
345

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Mar 2005

Geographic Reach
1 country

44 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2005

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2005

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

September 13, 2005

Completed
9 days until next milestone

First Posted

Study publicly available on registry

September 22, 2005

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2006

Completed
Last Updated

November 10, 2010

Status Verified

April 1, 2008

Enrollment Period

6 months

First QC Date

September 13, 2005

Last Update Submit

November 9, 2010

Conditions

Keywords

Chronic Obstructive Pulmonary DiseaseCOPDformoterol

Outcome Measures

Primary Outcomes (1)

  • Measure of lung function

Secondary Outcomes (2)

  • Change in lung function, as well as vital signs

  • Physical Exam results, Adverse event reporting, etc

Interventions

Eligibility Criteria

Age40 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Medical diagnosis of COPD
  • Current or prior history of cigarette smoking

You may not qualify if:

  • Medical diagnosis of asthma
  • Chest X-ray diagnostic of significant disease other than COPD
  • Significant condition or disease other than COPD

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (44)

Research Site

Jasper, Alabama, 35501, United States

Location

Research Site

Phoenix, Arizona, 85006-2666, United States

Location

Research Site

Tuscon, Arizona, 85715, United States

Location

Research Site

Buena Park, California, 90620, United States

Location

Research Site

Huntington Beach, California, 92647, United States

Location

Research Site

Long Beach, California, 90806, United States

Location

Research Site

Long Beach, California, 90813, United States

Location

Research Site

Los Angeles, California, 90048, United States

Location

Research Site

San Diego, California, 92120, United States

Location

Research Site

Stockton, California, 95207, United States

Location

Research Site

Denver, Colorado, 80206, United States

Location

Research Site

Wheat Ridge, Colorado, 80033, United States

Location

Research Site

Hartford, Connecticut, 06105, United States

Location

Research Site

Clearwater, Florida, 33765, United States

Location

Research Site

DeLand, Florida, 32720, United States

Location

Research Site

Tampa, Florida, 33603, United States

Location

Research Site

Woodstock, Georgia, 30189, United States

Location

Research Site

Hines, Illinois, 60141, United States

Location

Research Site

Normal, Illinois, 61761, United States

Location

Research Site

Florence, Kentucky, 41042, United States

Location

Research Site

New Orleans, Louisiana, 70115, United States

Location

Research Site

Ann Arbor, Michigan, 48106, United States

Location

Research Site

Minneapolis, Minnesota, 55402, United States

Location

Research Site

Rochester, Minnesota, 55905, United States

Location

Research Site

Saint Charles, Missouri, 63301, United States

Location

Research Site

St Louis, Missouri, 63122, United States

Location

Research Site

Butte, Montana, 59701, United States

Location

Research Site

Henderson, Nevada, 89014, United States

Location

Research Site

Cherry Hill, New Jersey, 08003, United States

Location

Research Site

Summit, New Jersey, 07901, United States

Location

Research Site

Albuquerque, New Mexico, 87108, United States

Location

Research Site

Camillus, New York, 13031, United States

Location

Research Site

Charlotte, North Carolina, 28207, United States

Location

Research Site

Cincinnati, Ohio, 45241, United States

Location

Research Site

Columbus, Ohio, 43215, United States

Location

Research Site

Medford, Oregon, 97504, United States

Location

Research Site

Portland, Oregon, 97213, United States

Location

Research Site

Cranston, Rhode Island, 02920, United States

Location

Research Site

Spartanburg, South Carolina, 29307, United States

Location

Research Site

Dallas, Texas, 75231, United States

Location

Research Site

San Antonio, Texas, 78229, United States

Location

Research Site

Richmond, Virginia, 23225, United States

Location

Research Site

Madison, Wisconsin, 53792, United States

Location

Research Site

Milwaukee, Wisconsin, 53209, United States

Location

Related Publications (2)

  • Nelson HS, Gross NJ, Levine B, Kerwin EM, Rinehart M, Denis-Mize K; Formoterol Study Group. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial. Clin Ther. 2007 Oct;29(10):2167-78. doi: 10.1016/j.clinthera.2007.10.007.

  • Gross NJ, Nelson HS, Lapidus RJ, Dunn L, Lynn L, Rinehart M, Denis-Mize K; Formoterol Study Group. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. Respir Med. 2008 Feb;102(2):189-97. doi: 10.1016/j.rmed.2007.10.007.

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

Formoterol Fumarate

Condition Hierarchy (Ancestors)

Lung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

EthanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsAmines

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

September 13, 2005

First Posted

September 22, 2005

Study Start

March 1, 2005

Primary Completion

September 1, 2005

Study Completion

September 1, 2006

Last Updated

November 10, 2010

Record last verified: 2008-04

Locations